Dr. Jacqueline Shea has served as INOVIO’s President and Chief Executive Officer (CEO) since May 2022. She is responsible for establishing and leading INOVIO’s overall corporate strategy across its clinical programs and advancing its DNA medicines platform.
Dr. Shea joined the Company in March 2019 as Chief Operating Officer (COO), serving as a key member of the executive team. She led INOVIO’s manufacturing, commercial, business development, project and alliance management operations.
Dr. Shea has more than 25 years’ experience in the life sciences and biotech industries. Prior to joining INOVIO, she was previously the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB). During her tenure she oversaw two major clinical trial breakthroughs in the development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium.
A molecular biologist and cell cycle geneticist by training, Dr. Shea has dedicated much of her career to developing innovative products to prevent and treat infectious diseases. She has been named as an inventor on more than 20 patents, is an author of numerous scientific publications, has served on multiple advisory boards and currently serves on the Board of Trustees for the Sabin Vaccine Institute. Dr. Shea received a BSc Hons in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.
As CFO, Mr. Kies’ primary focus is assuring INOVIO’s financial health as it reaches pipeline and commercialization goals in developing next-generation DNA medicines. As a key member of the executive leadership team, Mr. Kies is also responsible for developing and executing global financial strategy and action plans to meet the business objectives and to execute overall corporate strategy.
Prior to joining INOVIO in 2002, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from IPO to profitability. He was previously Chief Financial Officer at Newgen Results Corporation and held positions at Cytel Corporation and Ernst & Young, LLP. He has more than 30 years of experience developing and working with Biotechnology and High-Tech companies. Mr. Kies holds a B.S. degree in Business Administration from United States International University in San Diego, CA.
As Chief Scientific Officer, Dr. Humeau works to ensure continuous and strategic growth of INOVIO’s pipeline by introducing a constant flow of innovative concepts and cycling them from early-stage discovery and development through clinical application and patient monitoring. He provides technical and strategic leadership across multiple teams that are essential to upstream and downstream verticals of clinical development.
Dr. Humeau leads with a collaborative spirit and deeply believes in the company’s core values. He is a valuable member of the leadership team who greatly contributes to INOVIO’s culture. Prior to INOVIO, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Dr. Humeau holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 University and a MS degree from Pierre & Marie Curie/Paris 6 University, Paris, France.
Dr. Sumner leads INOVIO’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. Dr. Sumner previously served as CMO of Orexo AB since 2013. He previously held numerous European- and US-based leadership roles at Novartis Pharmaceuticals, Aventis Behring, Novo Nordisk and Shire Pharmaceuticals. Dr. Sumner brings over 25 years of extensive pharmaceutical, medical and clinical experience driving numerous late-stage product approvals and supporting successful commercial products on a global basis across multiple therapeutic areas.
Dr. Sumner received his medical degree from the University of London, is a member of the Royal College of Physicians, and holds a Master of Business Administration from Henley Management College, UK.
As Chief Commercial Officer, Commercial, Mr. Twyman has responsibility for leading INOVIO’s strategic and tactical commercial effort across the HPV-targeted, infectious diseases and immuno-oncology portfolios. Mr. Twyman has more than 20 years of healthcare commercial experience across multiple product categories including vaccines, pharmaceuticals, and medical devices. Prior to joining INOVIO, Mr. Twyman held key leadership roles including VP Marketing at Novavax, VP Marketing, Pediatric Vaccines at Merck, VP/GM Vaccines at MedImmune and SVP/GM, Biosurgery at Genzyme.
Mr. Twyman earned an MBA in Finance from The Wharton School of the University of Pennsylvania and a Bachelor of Arts degree in Economics from Dickinson College.
Mr. Crotty joined INOVIO as its new General Counsel in 2021. Mr. Crotty brings more than 15 years’ experience in the life sciences industry. Prior to joining INOVIO, Mr. Crotty held legal positions of increasing responsibilities at ImClone Systems Incorporated, NPS Pharmaceuticals, Dendron Corporation, Vernalis Therapeutics, and most recently, Nabriva Therapeutics where he served as General Counsel & Secretary. Before going in-house, Mr. Crotty was an associate at the global law firm of Morgan, Lewis & Bockius LLP, where his practice was focused on business and finance.
Mr. Crotty holds a JD from the University of Pennsylvania Law School and a BA from Princeton University. He is admitted to practice law in New York, New Jersey, and Pennsylvania.
Ms. Gevgilili joined INOVIO as Chief Human Resources Officer in 2021. She is responsible for the strategy, planning, and implementation of all human resource-related functions. Ms. Gevgilili joins INOVIO from Allergan (acquired by AbbVie), where she spent nearly 10 years in HR leadership roles of increasing responsibility; prior to Allergan, she spent eight years at Merck and Schering Plough, where she held HR Business Partner roles supporting different business functions.
Ms. Gevgilili holds a master’s degree in Industrial and Organizational Psychology from New York University and has completed graduate work at Baruch College towards her Ph.D. in Industrial and Organizational Psychology. She earned her BA in Psychology from Boğaziçi University in Istanbul.
Mr. Kim joined INOVIO as the President of INOVIO Asia in 2020 and was appointed to Chief Corporate Affairs Officer in 2021. In his role, Mr. Kim will oversee all communications functions for INOVIO, including investor and public relations. Mr. Kim brings more than 20 years of experience in finance and corporate strategy. Prior to joining INOVIO, in his last three roles as CFO of public and private companies in Korea, Gene had strong investor relations experiences where he built high-performing investor relations teams, improved company presence among investors and increased analyst coverage by securities firms.
Mr. Kim holds an MBA from the Wharton School of the University of Pennsylvania and a BS in Chemical Engineering from the University of California, Los Angeles.
Mr. Brandreth is responsible for all quality and compliance functions across clinical development, manufacturing and other operational areas that support INOVIO’s broad pipeline of DNA medicines. With over 30 years in life sciences including small molecules, devices and a wide variety of pivotal biotechnology products, Mr. Brandreth is a key member of the senior leadership team with a track record of moving pipeline candidates such as Rituxan®, Zevalin®, Aldurazyme® and Naglazyme® to commercialization. Mr. Brandreth will play a critical role as INOVIO ramps up its DNA medicines into late-stage clinical trials.
Prior to joining INOVIO, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he contributed to the success of several biopharmaceutical companies through his strong leadership of the quality and compliance areas. He holds an MBA from University of the Pacific and a B.A. in Biology from University of California, San Diego.
As Senior Vice President of Business Development, Mr. Bridy is responsible for Business Development and Licensing activities at INOVIO. Mr. Bridy has over 20 years of business development, licensing, strategy, and transaction experience. Prior to joining INOVIO, Mr. Bridy was a strategic and operational advisor to over 20 life sciences operating and investment companies. Mr. Bridy also served as Head of Business Development and Licensing for Immunome, an emerging immuno-oncology company, and was a key member of the team that raised a $17.2M Series-A. At Elan Pharmaceuticals, he was responsible for out-licensing an oncology and neuroscience portfolio in their Business Development group. At GlaxoSmithKline, Mr. Bridy was responsible for diligence and valuation of oncology in-licensing and pipeline drugs in their Global Commercial Strategy group. He also served as Vice President of Strategy and Business Development at BTG plc.
Mr. Bridy has an MA in Biology and an MBA in Finance from Villanova University and a BA and BS degree in Zoology from Miami University.
As Senior Vice President of Regulatory Affairs, Dr. Elder is responsible for the development of regulatory strategies and company interaction with regulatory authorities globally. She is a proven leader with over 20 years of experience leading multi-cultural, cross-functional teams in drug development and regulatory strategies across multiple therapeutic areas. Most recently Dr. Elder was the Global Regulatory Head for the Hematology Development Unit at Novartis.
Dr. Elder received her Doctor of Pharmacy degree from Philadelphia College of Pharmacy and Science and completed her industrial clinical pharmacy practice fellowship at Rutgers University and Hoffmann-La Roche. She is also a graduate of the University of Kentucky, where she received her BS from the College of Pharmacy.
Mr. Jordan is responsible for overall supply chain operations at INOVIO, where he drives departmental cohesiveness with purpose and vision to meet company commercialization goals. With over 25 years of experience in the medical device and environmental health and safety industries, Mr. Jordan has led many successful operational teams ranging from start-ups through large organizational IPOs. His technical and executional strengths are great assets to the company.
As a senior leader at INOVIO, Mr. Jordan is known for his dedication and meticulous approach that motivate innovative solutions and positive outcomes across all Materials departments while increasing stakeholder value and satisfaction. Mr. Jordan received an MBA in Finance from George Herbert Walker School of Business & Technology at Webster University and holds a B.S. in Business Management from San Diego State University.
Mr. Juba is responsible for ensuring the manufacturing and supply of INOVIO’s precisely designed and delivered DNA medicines and vaccine candidates for clinical use. He provides strategic and operational leadership of Supply Operations function, establishing supply processes, planning, procurement, and inventory strategies for late-stage clinical programs as well as new product launches and product line extensions.
As a chemical engineer with 20+ years of experience managing cGMP pharmaceutical and biological vaccine manufacturing for commercial and clinical products, Mr. Juba leads with extensive technical expertise to help INOVIO reach product development and commercialization goals. He previously led plasmid manufacturing at VGXI, Inc. and held several positions at Merck in bulk vaccine manufacturing operations and strategy. Mr. Juba holds a Master of Science degree in Chemical Engineering Practice and a BS degree in Chemical Engineering, both from the Massachusetts Institute of Technology.
Mr. Kemmerrer is responsible for electrical and mechanical engineering, software development and human factors for current and new device technologies used in the delivery of INOVIO’s DNA medicines. He is a well-respected and seasoned engineer who leads with an entrepreneurial spirit and brings years of experience in implementing innovative, high-impact solutions in the Biotech industry including as a developer of the Advanced Tissue Sciences human tissue mesh technology. Earlier in his career, he worked in the aerospace field building communication satellites.
Mr. Kemmerrer believes in a disciplined and focused approach to achieving strategic goals and is driven to improve patient outcomes across multiple therapeutic areas and patient populations, especially children. Mr. Kemmerrer holds a B.S. in Mechanical Engineering from University of California, Berkeley and an MBA from San Diego State University.
Dr. Skolnik leads INOVIO’s clinical development programs, focusing on HPV and immuno-oncology DNA medicines. He is a key member of the leadership team overseeing these global clinical assets. Dr. Skolnik has held several leadership positions in Clinical Development and Medical Affairs for AstraZeneca, GSK, and TetraLogic Pharmaceuticals, for both early- and late-stage compounds. Dr. Skolnik is a board-certified pediatric hematologist/oncologist and is an Attending Physician at the Children’s Hospital of Philadelphia.
Simon Benito has been a director of INOVIO since 2003. Mr. Benito is also a director of Durect Corporation, a specialty pharmaceutical company. Mr. Benito has had a successful and extensive career serving multiple healthcare companies in senior executive positions, including 25 years at Merck & Co, Inc. where he served as Senior Vice President, Merck Vaccine Division from 1996 to 1999; Executive Vice President, Merck-Medco Managed Care from 1994 to 1996; and Executive Director and Vice President, Merck Human Health, Japan from 1986-1993. Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over thirty years until his retirement from Merck in 1999.
Dr. Roger Dansey joined Seagen as Chief Medical Officer in 2018, bringing extensive experience in cancer drug development. His deep oncology background and proven leadership has helped Seagen evolve into a global, multi-product oncology company.
Previously, Dr. Dansey was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda® (pembrolizumab) across multiple tumor types. Earlier in his career, Dr. Dansey was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
Dr. Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.
Dr. Jacqueline Shea has served as INOVIO’s President and Chief Executive Officer (CEO) since May 2022. She is responsible for establishing and leading INOVIO’s overall corporate strategy across its clinical programs and advancing its DNA medicines platform.
Dr. Shea joined the Company in March 2019 as Chief Operating Officer (COO), serving as a key member of the executive team. She led INOVIO’s manufacturing, commercial, business development, project and alliance management operations.
Dr. Shea has more than 25 years’ experience in the life sciences and biotech industries. Prior to joining INOVIO, she was previously the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB). During her tenure she oversaw two major clinical trial breakthroughs in the development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium.
A molecular biologist and cell cycle geneticist by training, Dr. Shea has dedicated much of her career to developing innovative products to prevent and treat infectious diseases. She has been named as an inventor on more than 20 patents, is an author of numerous scientific publications, has served on multiple advisory boards and currently serves on the Board of Trustees for the Sabin Vaccine Institute. Dr. Shea received a BSc Hons in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.
Dr. Ann Miller joined our Board in March 2019 and brings her years of commercial experience in the biopharmaceutical industry and her clinical training. Dr. Miller is also a Director at Puma Biotechnology and Allena Pharmaceuticals. Dr. Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr. Miller served as Senior Vice President at Eisai Co., Ltd., leading the Primary Care and Specialty Business unit and then Pharmaceutical Services. Dr. Miller previously served in management roles in global and U.S. marketing at Amgen Inc. for five years and in positions of increasing responsibility at Merck & Co., Inc. over 16 years. Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in Chemistry, summa cum laude, from Duke University.
Jay P. Shepard served as Executive Chairman of Versartis, Inc., from December 2013 to 2015. In May 2015, Mr. Shepard joined Versartis as President and CEO. In 2018, Versartis merged with Aravive (NASDAQ: ARAV) and he served as the President and Chief Executive Officer from May 2018 to January 2020, when he retired. From 2008 to 2015, Mr. Shepard was the Executive Partner at Sofinnova Ventures. Previously, he was the President and Chief Executive Officer of NextWave Pharmaceuticals (acquired by Pfizer), President and Chief Executive Officer of Ilypsa (acquired by Amgen), interim President and Chief Executive Officer of Relypsa (Ilypsa’s spin-out company, which was acquired by Galencia), and Vice President of Commercial Operations at Telik and Oncology Business Unit Head of Alza Pharmaceuticals (Alza was acquired by Johnson & Johnson). He has over 35 years of experience in the pharmaceutical, biotechnology, and drug delivery arenas. He has participated in or led over 16 product launches by preparing markets and establishing sales and marketing operations. Mr. Shepard currently serves as the Chairman of the Board of the Christopher & Dana Reeve Foundation. He is a board member of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), Esperion (NASDAQ: ESPR) and Craig Hospital. Mr. Shepard is an operating partner at Catalys Pacific, a venture group focused on licensing drug programs and creating new companies in the US and Japan. Mr. Shepard holds a B.S. in business administration from the University of Arizona.
David Weiner is Executive Vice President of The Wistar Institute, Director of its Vaccine Center, and the W.W. Smith Charitable Trust Endowed Professorship in Cancer Research. The Wistar Institute is the nation’s first independent biomedical research institute, NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research. Previously, Dr. Weiner was Professor, Department of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine and co-leader of the Tumor Virology Program of the Abramson Cancer Center at Penn.
Dr. Weiner is a world-renowned leader in immunology as well as gene vaccines and immunotherapy. In scientific circles he is known as the “father of DNA vaccines.” He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world.
An inventor of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors, including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and the Vaccine Industry Excellence Award for Best Academic Research Team at the World Vaccine Congress in 2015 and again in 2016. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy.
David Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati, and a B.S. in biology from SUNY at Stoney Brook in Stoney Brook, New York.
Wendy L. Yarno has over 26 years’ experience in the pharmaceutical industry with Merck & Co., Inc. and Johnson & Johnson. She has held a number of executive positions in the marketing, sales, human resources, and policy areas. She most recently was Executive Vice President and Chief Marketing Officer at Merck & Co., Inc. and retired from Merck in 2008.
Ms. Yarno has extensive experience as a director on both public and private company boards. She currently is the non-executive Chairman of the Board for Aratana Therapeutics, and is a member of the board of Alder Biopharmaceuticals, Global Blood Therapeutics, and MyoKardia, Inc. She was previously a member of the Board of Directors of St. Jude Medical Inc., Medivation, Inc., Durata Therapeutics, PluroGen Therapeutics, and ADial Pharmaceuticals.
Ms. Yarno has an MBA from Temple University in Philadelphia, PA and a B.S. in Marketing from Portland State University in Portland, OR.
Lota Zoth has served as a director of INOVIO since January 2019. Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Chief Accounting Officer and Controller for various publicly traded companies, including MedImmune, Inc., PSINet, Inc. and Sodexho Marriott, and as a financial executive in various roles at Marriott International, Pepsi-Cola International and PepsiCo.
Ms. Zoth began her career as an auditor with Ernst & Young. Ms. Zoth serves on the boards of four publicly traded biopharmaceutical companies (NewLink Genetics Corporation, Orexigen Therapeutics, Inc., Spark Therapeutics, Inc. and Zymeworks, Inc.) and serves on the audit committees of three of them (NewLink, Spark and Zymeworks). Previously, Ms. Zoth served on the boards of four other biopharmaceutical companies (Aeras, Circassia Pharmaceuticals, plc, Hyperion Therapeutics, Inc. and Ikaria, Inc.).
Ms. Zoth holds a Bachelor of Business Administration in Accounting, summa cum laude, from Texas Tech University.
Dr. Rafi Ahmed is the Georgia Research Alliance Professor of Microbiology and Immunology, and Director of the Emory Vaccine Center at Emory University School of Medicine in Atlanta, GA. His research efforts are directed towards: 1. Understanding the mechanisms of immunological memory and using this knowledge to develop new and more effective vaccines. 2. Defining the mechanisms of T cell exhaustion during chronic viral infections and cancer and developing strategies for restoring function in exhausted T cells. Dr. Ahmed is a member of the National Academy of Sciences and the National Academy of Medicine.
Anthony Ford-Hutchinson has over 30 years’ experience in vaccine development and commercialization and was formerly at Merck and Co. During his tenure at Merck, Dr. Ford-Hutchinson played a leadership role in the development of several new blockbuster vaccines, including Gardasil®, Zostavax®, Proquad®, and Rotateq®. He was also responsible for the development of many important Merck drugs, including Singulair®, Arcoxia®, and Isentress® for asthma, pain/inflammation, and the treatment of HIV infection.
Dr. Ford-Hutchinson, who retired from Merck in early 2012, was most recently Senior Vice President, Vaccines Research and Development, and Chairman of the Board of Directors for MSD Wellcome Trust Hilleman Labs. He has held many other prominent positions at Merck in Canada and the USA, including Executive Vice President for Worldwide Research. He was responsible for all strategic decisions in Merck’s vaccine R&D following appointment as franchise head in 2005, producing a pipeline with three vaccines in phase III trials and a number of others in earlier development. He obtained his Bachelor’s degree in biochemistry from the University of Birmingham, a Master’s in molecular enzymology from the University of Warwick, and a Ph.D. in biochemistry from the University of London.
Stanley Plotkin developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines, including polio, rabies, varicella, rotavirus, and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and is a principal of Vaxconsult.
Over the course of his career he has served as senior assistant surgeon with the Epidemic Intelligence Service of the U.S. Public Health Service; Chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics; Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health; director of the Division of Infectious Diseases at Children’s Hospital of Philadelphia; Associate Chairman of the Department of Pediatrics, University of Pennsylvania; Medical and Scientific Director of Aventis Pasteur; and Executive Advisor to Sanofi Pasteur. Over 600 of his articles have been published, and he has edited several books, including Vaccines, now the standard textbook in the field.
Dr. Plotkin’s numerous professional awards include:
Dr. Plotkin earned his M.D. at the State University of New York, Downstate College of Medicine, and holds honorary degrees from the University of Pennsylvania and the University of Rouen (France). He serves on the Board of Directors of Dynavax and is Chairman of the Scientific Advisory Board of Mymetics, while also serving as an International Society for Vaccines advisor.
David Weiner is Executive Vice President of The Wistar Institute, Director of its Vaccine Center, and the W.W. Smith Charitable Trust Endowed Professorship in Cancer Research. The Wistar Institute is the nation’s first independent biomedical research institute, NCI-designated Cancer Center, and an international leader in cancer, immunology and infectious disease research. Previously, Dr. Weiner was Professor, Department of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine and co-leader of the Tumor Virology Program of the Abramson Cancer Center at Penn.
Dr. Weiner is a world-renowned leader in immunology as well as gene vaccines and immunotherapy. In scientific circles he is known as the “father of DNA vaccines.” He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world.
An inventor of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors, including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and the Vaccine Industry Excellence Award for Best Academic Research Team at the World Vaccine Congress in 2015 and again in 2016. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy.
David Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati, and a B.S. in biology from SUNY at Stoney Brook in Stoney Brook, New York.
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.
